PSCH - ETF AI Analysis
Top Page
Invesco S&P SmallCap Health Care ETF (PSCH)
Rating:67Neutral
Price Target:―
Positive Factors
Strong Recent Performance
The ETF has shown strong gains so far this year and in recent months, indicating solid momentum in its small-cap health care holdings.
Top Holdings Showing Solid Gains
Many of the largest positions, including several biotech and health care names, have delivered strong year-to-date performance, helping drive the fund’s returns.
Focused Exposure to U.S. Health Care
The fund is heavily invested in U.S. health care companies, giving investors targeted exposure to a sector with steady long-term demand.
Negative Factors
Sector Concentration Risk
With most assets in health care, the ETF is vulnerable if this single sector faces regulatory changes, reimbursement pressure, or other industry-specific challenges.
Limited Geographic Diversification
Almost all holdings are U.S.-based, so investors get little protection if the U.S. market or economy experiences a downturn.
Small-Cap Volatility
Because the fund focuses on small-cap companies, its share price can be more volatile and sensitive to market swings than large-cap or more diversified ETFs.
PSCH vs. SPDR S&P 500 ETF (SPY)
AUM168.00M
RegionNorth America
Expense Ratio0.29%
Beta0.82
IssuerInvesco
Inception DateApr 07, 2010
Dividend Yield0.04%
Asset ClassEquity
Index TrackedS&P SmallCap 600 Capped Health Care Index - Benchmark TR Gross
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume35,616
30 Day Avg. Volume20,831
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
64.61Price Target Upside― Downside
Rating ConsensusModerate Buy
Number of Analyst Covering70
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
PSCH Summary
PSCH is an ETF that focuses on smaller U.S. health care companies by following the S&P SmallCap 600 Capped Health Care Index. It owns a mix of businesses in areas like drugs, biotech, medical devices, and health care services. Well-known holdings include Molina Healthcare and Teleflex. Investors might consider PSCH if they want growth potential from newer, more agile health care companies while still spreading their money across many stocks. A key risk is that small health care companies can be very volatile, so the ETF’s price can move up and down sharply with changes in the market and the health care sector.
How much will it cost me?The Invesco S&P SmallCap Health Care ETF (PSCH) has an expense ratio of 0.29%, meaning you’ll pay $2.90 per year for every $1,000 invested. This cost is slightly higher than average because the ETF focuses on a niche sector and tracks small-cap health care companies, which require more active management compared to broad-market passive ETFs.
What would affect this ETF?The Invesco S&P SmallCap Health Care ETF (PSCH) could benefit from advancements in biotechnology, pharmaceuticals, and medical devices, as small-cap companies often drive innovation in the health care sector. However, it may face challenges from rising interest rates, which can increase borrowing costs for smaller companies, and regulatory changes in the U.S. health care industry that could impact profitability. The ETF’s focus on U.S. small-cap health care stocks makes it sensitive to domestic economic conditions and sector-specific trends.
PSCH Top 10 Holdings
PSCH is essentially a small‑cap health care lab, with a handful of fast-moving biotech names setting the tone. Rising stars like Corcept Therapeutics, Glaukos, Protagonist Therapeutics, and Liquidia Technologies have been powering the fund lately, helped by upbeat momentum and product news. On the flip side, Alkermes and PTC Therapeutics have been more mixed, occasionally losing steam and tempering overall gains. With almost all exposure in U.S. health care and a tilt toward smaller drug developers and med‑tech firms, the ETF is concentrated but geared toward innovation-driven growth.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Corcept Therapeutics | 5.78% | $9.62M | $12.38B | 65.93% | 76 Outperform | |
| Glaukos | 5.06% | $8.43M | $9.83B | 93.50% | 61 Neutral | |
| Protagonist Therapeutics | 4.29% | $7.13M | $8.79B | 153.84% | 68 Neutral | |
| Alkermes | 4.27% | $7.10M | $8.22B | 84.52% | 80 Outperform | |
| TG Therapeutics | 3.61% | $6.01M | $7.96B | 48.57% | 65 Neutral | |
| PTC Therapeutics | 3.20% | $5.33M | $5.68B | 30.46% | 72 Outperform | |
| Liquidia Technologies | 3.12% | $5.19M | $7.48B | 375.74% | 57 Neutral | |
| Ligand Pharma | 3.04% | $5.05M | $5.76B | 116.65% | 60 Neutral | |
| Teleflex | 3.00% | $4.99M | $6.05B | 17.96% | 68 Neutral | |
| Merit Medical Systems | 2.54% | $4.23M | $5.08B | 0.27% | 68 Neutral |
PSCH Technical Analysis
Positive
―
Price Trends
50.06
Positive
46.43
Positive
45.17
Positive
Market Momentum
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For PSCH, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 53.51, equal to the 50-day MA of 50.06, and equal to the 200-day MA of 45.17, indicating a neutral trend. The MACD of ― indicates undefined momentum. The RSI at ― is undefined, neither overbought nor oversold. The STOCH value of ― is undefined, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for PSCH.
PSCH Peer Comparison
Comparison Results
Performance Comparison
PSCH
Invesco S&P SmallCap Health Care ETF
53.39
15.06
39.29%
FTXH
First Trust Nasdaq Pharmaceuticals ETF
―
―
―
RSPH
Invesco S&P 500 Equal Weight Health Care ETF
―
―
―
XPH
SPDR S&P Pharmaceuticals ETF
―
―
―
PINK
Simplify Health Care ETF
―
―
―
PTH
Invesco DWA Healthcare Momentum ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
DisclaimerThis AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents